Attention Deficit Hyperactivity Disorder (ADHD) Medications and Heart Failure

    Basic Details
    Date Posted
    Tuesday, October 25, 2016
    Status
    Complete
    Medical Product
    amphetamine
    methylphenidate
    Strattera
    Health Outcome(s)
    heart failure
    Description

    Modular program-based one-time assessment of heart failure diagnoses following new attention deficit hyperactivity disorder (ADHD) medication use. The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2000 through March 3, 2016. Modular programs are adaptable standardized programs. Results were generated using the Cohort Identification and Descriptive Analysis (CIDA) tool, click here for more information. Queries were distributed in March 2016. These reports include data from 15 Data Partners.

    If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@sentinelsystem.org.

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    2000 - 2016
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Sentinel Distributed Database (SDD)